Literature DB >> 1545347

Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-converting enzyme.

J P Bai1, M Hu, P Subramanian, H I Mosberg, G L Amidon.   

Abstract

The feasibility of targeting prolidase as a peptide prodrug-converting enzyme has been examined. The enzymatic hydrolysis by prolidase of substrates for the peptide transporter L-alpha-methyldopa-pro and several dipeptide analogues without an N-terminal alpha-amino group (phenylpropionylproline, phenylacetylproline, N-benzoylproline, and N-acetylproline) was investigated. The Michaelis-Menten parameters Km and Vmax for L-alpha-methyldopa-pro are 0.09 +/- 0.02 mM and 3.98 +/- 0.25 mumol/min/mg protein, respectively. However, no hydrolysis of the dipeptide analogues without an N-terminal alpha-amino group is observed, suggesting that an N-terminal alpha-amino group is required for prolidase activity. These results demonstrate that prolidase may serve as a prodrug-converting enzyme for the dipeptide-type prodrugs, utilizing the peptide carrier for transport of prodrugs into the mucosal cells and prolidase, a cytosolic enzyme, to release the drug. However, a free alpha-amino group appears to be necessary for prolidase hydrolysis.

Entities:  

Keywords:  NASA Discipline Regulatory Physiology; Non-NASA Center

Mesh:

Substances:

Year:  1992        PMID: 1545347     DOI: 10.1002/jps.2600810202

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Oligopeptide transport by epithelial cells.

Authors:  D Meredith; C A Boyd
Journal:  J Membr Biol       Date:  1995-05       Impact factor: 1.843

3.  Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).

Authors:  J P Bai; M J Hsu; W T Shier
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 4.  Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery.

Authors:  J P Bai; G L Amidon
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

5.  Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease.

Authors:  Arik Dahan; Milica Markovic; Shahar Keinan; Igor Kurnikov; Aaron Aponick; Ellen M Zimmermann; Shimon Ben-Shabat
Journal:  J Comput Aided Mol Des       Date:  2017-11-03       Impact factor: 3.686

6.  Transepithelial transport of insulin: I. Insulin degradation by insulin-degrading enzyme in small intestinal epithelium.

Authors:  J P Bai; L L Chang
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

7.  pGlu-L-Dopa-Pro: a tripeptide prodrug targeting the intestinal peptide transporter for absorption and tissue enzymes for conversion.

Authors:  J P Bai
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

8.  Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma.

Authors:  Sachin Mittal; Xueqin Song; Balvinder S Vig; Gordon L Amidon
Journal:  Pharm Res       Date:  2007-03-22       Impact factor: 4.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.